Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
0.1499
Nov 17 • 10:23 AM ET Dollar change+0.0048 Percentage change(3.31%)
Index
-
Market Cap
10.16M
Enterprise Value
26.40M
Income
-115.09M
Sales
5.19M
Book/sh
0.56
Cash/sh
1.08
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
142
IPO
Jul 16, 2021
P/E
-
Forward P/E
-
PEG
-
P/S
1.96
P/B
0.27
P/C
0.14
P/FCF
-
EV/EBITDA
-
EV/Sales
5.09
Quick Ratio
2.03
Current Ratio
2.03
Debt/Eq
2.35
LT Debt/Eq
1.73
Option/Short
No / Yes
EPS (ttm)
-0.89
EPS next Y
-0.56
EPS next Q
-0.16
EPS this Y
12.75%
EPS next Y
36.10%
EPS next 5Y
20.98%
EPS past 3/5Y
28.66% 2.08%
Sales past 3/5Y
-8.63% 56.92%
EPS Y/Y TTM
20.89%
Sales Y/Y TTM
-38.43%
EPS Q/Q
7.49%
Sales Q/Q
-76.66%
Insider Own
21.33%
Insider Trans
0.00%
Inst Own
49.01%
Inst Trans
27.61%
ROA
-57.03%
ROE
-126.45%
ROIC
-111.11%
Gross Margin
46.14%
Oper. Margin
-2161.53%
Profit Margin
-2219.19%
SMA20
-19.35%
SMA50
-40.14%
SMA200
-81.16%
Trades
Shs Outstand
63.50M
Shs Float
53.32M
52W High
1.47 -89.80%
52W Low
0.15 3.31%
Volatility
11.83% 10.65%
ATR (14)
0.02
RSI (14)
30.22
Beta
1.22
Rel Volume
0.38
Avg Volume
750.83K
Volume
53,048
Perf Week
-19.06%
Perf Month
-28.69%
Perf Quarter
-80.01%
Perf Half Y
-84.44%
Perf YTD
-85.01%
Perf Year
-84.55%
Perf 3Y
-97.20%
Perf 5Y
-98.33%
Perf 10Y
-
Prev Close
0.15
Price
0.15
Change %
3.31%
Consensus
Hold
Avg. Price Target
$2.67
Implied Upside
+1,681.2%
Analysts5incl. previous ratings
Rating Distribution3 Buy · 2 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Sep 08, 2026Downgrade
HH.C. Wainwright
Buy → Neutral$1+567.1%
Nov 14, 2025Downgrade
MS logoMMorgan Stanley
Overweight → Equal-Weight
May 16, 2024Initiated
BBTIG Research
Buy$12+7,905.3%
May 13, 2024Initiated
NNeedham
Buy$11+7,238.2%
Jun 22, 2023Initiated
WWedbush
Outperform$8+5,236.9%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lynx1 Capital Management LP10% OwnerDec 19 '25Buy0.9080,06971,9747,937,416Dec 23 06:17 PM
Lynx1 Capital Management LP10% OwnerDec 22 '25Buy0.9075,50067,9508,012,916Dec 23 06:17 PM
Lynx1 Capital Management LP10% OwnerDec 23 '25Buy0.906,2325,6028,019,148Dec 23 06:17 PM
TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Waltham, MA.
CEODr. Gavin MacBeath Ph.D.
Co-Founder & Chairman of Scientific Advisory BoardDr. Stephen J. Elledge Ph.D.
Co-Founder & Member of Advisory BoardMr. Tomasz Kula Ph.D.
Ph.D.Dr. Zoran Zdraveski J.D.
Chief Human Resources OfficerMs. Ann Hargraves